J Korean Liver Cancer Stud Search

CLOSE


J Liver Cancer > Volume 14(1); 2014 > Article
Journal of the Korean Liver Cancer Study 2014;14(1):1-6.
DOI: https://doi.org/10.17998/jlc.14.1.1    Published online March 31, 2014.
Radioembolization in Hepatocellular Carcinoma
Ho Jong Chun
Department of Radiology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea
Correspondence:  Ho Jong Chun,
Email: chunray@catholic.ac.kr
Copyright ©2014 by The Korean Liver Cancer Association
Abstract
Radioembolization is an emerging treatment modality in patients with hepatocellular carcinoma (HCC) and is a form of brachytherapy in which intra-arterially injected Ytrrium-90 microspheres are used for internal radiation purpose. Ytrrium-90 is a high energy beta particle-emitting radioisotope. Ytrrium-90 microspheres administered via arterial route direct the highly concentrated radiation to the tumor while normal liver parenchyma is relatively spared due to its preferential blood supply from portal venous blood. Main complications do not result from the microembolic effect, even in patients with portal vein thrombosis, but rather from an excessive irradiation to the non-target tissues including the liver. All the evidence that support the use of radioembolization in HCC is based on retrospective series or non-controlled prospective studies. However, reliable data can be obtained from the literature, particularly since the recent publication of large series. When compared to the standard of treatment for the intermediate and advanced stages (TACE and sorafenib), radioembolization consistently provides similar survival rates. Many randomized controlled trials using radioembolization are underway and will provide optimal evidences as standard treatment for unresectable HCC.
Key Words: Hepatocellular carcinoma; Radioembolization
NULL


ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
1527 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2019 by The Korean Liver Cancer Association. All rights reserved.

Developed in M2community

Close layer
prev next